{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:27:46Z","timestamp":1791167266559,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1038\/sj.bjc.6601579","type":"journal-article","created":{"date-parts":[[2004,3,2]],"date-time":"2004-03-02T18:18:31Z","timestamp":1078251511000},"page":"955-961","source":"Crossref","is-referenced-by-count":121,"title":["Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers"],"prefix":"10.1038","volume":"90","author":[{"given":"J B","family":"Bartlett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I A","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Dredge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Kristeleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Polychronis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Pandha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G W","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D I","family":"Stirling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Zeldis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A G","family":"Dalgleish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2004,3,2]]},"reference":[{"key":"BF6601579_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1089\/aid.1997.13.301","volume":"13","author":"LN Alexander","year":"1997","unstructured":"Alexander LN, Wilcox CM (1997) A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers. AIDS Res Hum Retroviruses 13: 301\u2013304","journal-title":"AIDS Res Hum Retroviruses"},{"key":"BF6601579_CR2","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1182\/blood.V92.12.4491","volume":"92","author":"JO Armitage","year":"1998","unstructured":"Armitage JO (1998) Emerging applications of recombinant human granulocyte\u2013macrophage colony-stimulating factor. Blood 92: 4491\u20134508","journal-title":"Blood"},{"key":"BF6601579_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/00001622-199703000-00016","volume":"9","author":"MB Atkins","year":"1997","unstructured":"Atkins MB (1997) The treatment of metastatic melanoma with chemotherapy and biologics. Curr Opin Oncol 9: 205\u2013213","journal-title":"Curr Opin Oncol"},{"key":"BF6601579_CR4","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","volume":"163","author":"LG Corral","year":"1999","unstructured":"Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-\u03b1. J Immunol 163: 380\u2013386","journal-title":"J Immunol"},{"key":"BF6601579_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/blood.V98.1.210","volume":"98","author":"FE Davies","year":"2001","unstructured":"Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98: 210\u2013216","journal-title":"Blood"},{"key":"BF6601579_CR6","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/sj.bjc.6600607","volume":"87","author":"K Dredge","year":"2002","unstructured":"Dredge K, Marriott JB, Macdonald CD, Man H-W, Chen R, Muller GW, Stirling D, Dalgleish AG (2002a) Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 87: 1166\u20131172","journal-title":"Br J Cancer"},{"key":"BF6601579_CR7","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.4049\/jimmunol.168.10.4914","volume":"168","author":"K Dredge","year":"2002","unstructured":"Dredge K, Marriott JB, Todryk SM, Muller GW, Chen R, Stirling DI, Dalgleish AG (2002b) Protective anti-tumour immunity induced by a costimulatory thalidomide analog in conjunction with whole tumour cell vaccination is mediated by increased Th1-type immunity. J Immunol 168: 4914\u20134919","journal-title":"J Immunol"},{"key":"BF6601579_CR8","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/S0016-5085(99)70276-3","volume":"117","author":"ED Ehrenpreis","year":"1999","unstructured":"Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB (1999) Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 117: 1271\u20131277","journal-title":"Gastroenterology"},{"key":"BF6601579_CR9","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1054\/bjoc.1999.1004","volume":"82","author":"T Eisen","year":"2000","unstructured":"Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, Ahern R, Smith IE, Gore ME (2000) Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82: 812\u2013817","journal-title":"Br J Cancer"},{"key":"BF6601579_CR10","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1200\/JCO.2002.20.11.2607","volume":"20","author":"T Eisen","year":"2002","unstructured":"Eisen T (2002) Thalidomide in solid malignancies. J Clin Oncol 20: 2607\u20132608","journal-title":"J Clin Oncol"},{"key":"BF6601579_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1258\/0956462981921512","volume":"9","author":"K Fife","year":"1998","unstructured":"Fife K, Howard MR, Gracie F, Phillips RH, Bower M (1998) Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS 9: 751\u2013755","journal-title":"Int J STD AIDS"},{"key":"BF6601579_CR12","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1200\/JCO.2000.18.4.708","volume":"18","author":"HA Fine","year":"2000","unstructured":"Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK (2000) Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18: 708\u2013715","journal-title":"J Clin Oncol"},{"key":"BF6601579_CR13","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1046\/j.1365-2141.2000.02239-11.x","volume":"110","author":"J Gutheil","year":"2000","unstructured":"Gutheil J, Finucane D (2000) Thalidomide therapy in refractory solid tumour patients. Br J Haematol 110: 754","journal-title":"Br J Haematol"},{"key":"BF6601579_CR14","doi-asserted-by":"publisher","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","volume":"128","author":"V Hamuryudan","year":"1998","unstructured":"Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Silva A, Yurdakal S, Zwingenberger K, Yazici H (1998) Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128: 443\u2013450","journal-title":"Ann Intern Med"},{"key":"BF6601579_CR15","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1084\/jem.187.11.1885","volume":"187","author":"PA Haslett","year":"1998","unstructured":"Haslett PA, Corral LG, Albert M, Kaplan G (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187: 1885\u20131892","journal-title":"J Exp Med"},{"key":"BF6601579_CR16","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1054\/bjoc.1999.1034","volume":"82","author":"AG Heriot","year":"2000","unstructured":"Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG (2000) Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer 82: 1009\u20131012","journal-title":"Br J Cancer"},{"key":"BF6601579_CR17","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","volume":"96","author":"T Hideshima","year":"2000","unstructured":"Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling D, Anderson KC (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96: 2943\u20132950","journal-title":"Blood"},{"key":"BF6601579_CR18","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJM199705223362103","volume":"336","author":"JM Jacobson","year":"1997","unstructured":"Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, Fox L, Chernoff M., Wu AW, MacPhail LA, Vasquez GJ, Wohl DA (1997) Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 336: 1487\u20131493","journal-title":"N Engl J Med"},{"key":"BF6601579_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1046\/j.1365-2141.2000.01983.x","volume":"109","author":"G Juliusson","year":"2000","unstructured":"Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C (2000) Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 109: 89\u201396","journal-title":"Br J Haematol"},{"key":"BF6601579_CR20","first-page":"247","volume":"11","author":"JD Klausner","year":"1996","unstructured":"Klausner JD, Makonkawkeyoon S, Akarasewi P, Nakata K, Kasinrerk W, Corral L, Dewar RL, Lane HC, Freedman VH, Kaplan G (1996) The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J AIDS 11: 247\u2013257","journal-title":"J AIDS"},{"key":"BF6601579_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1046\/j.1365-2141.2000.01835.x","volume":"108","author":"A Kneller","year":"2000","unstructured":"Kneller A, Raanani P, Hardan I, Avigdor A, Levi I, Berkowicz M, Ben-Bassat I (2000) Therapy with thalidomide in refractory multiple myeloma patients \u2013 the revival of an old drug. Br J Haematol 108: 391\u2013393","journal-title":"Br J Haematol"},{"key":"BF6601579_CR22","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S0167-5699(99)01531-5","volume":"583","author":"JB Marriott","year":"1999","unstructured":"Marriott JB, Muller G, Dalgleish AG (1999) Thalidomide as an emerging immunotherapeutic agent. Immunol Today 583: 538\u2013540","journal-title":"Immunol Today"},{"key":"BF6601579_CR23","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1517\/14712598.1.4.675","volume":"1","author":"JB Marriott","year":"2001","unstructured":"Marriott JB, Muller GW, Stirling D, Dalgleish AG (2001) Immunotherapeutic and anti-tumour potential of thalidomide analogues. Exp Opin Biol Ther 1: 675\u2013682","journal-title":"Exp Opin Biol Ther"},{"key":"BF6601579_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1046\/j.1365-2141.2001.03142.x","volume":"115","author":"K Neben","year":"2001","unstructured":"Neben K, Moehler T, Kraemer A, Benner A, Egerer G, Ho AD, Goldschmidt H (2001) Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol 115: 605\u2013608","journal-title":"Br J Haematol"},{"key":"BF6601579_CR25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/00000421-200006000-00023","volume":"23","author":"YZ Patt","year":"2000","unstructured":"Patt YZ, Hassan MM, Lozano RD, Ellis LM, Petersson JA, Waugh KA (2000) Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 23: 319\u2013321","journal-title":"Am J Clin Oncol"},{"key":"BF6601579_CR26","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1056\/NEJM199911183412110","volume":"341","author":"N Raje","year":"1999","unstructured":"Raje N, Anderson K (1999) Thalidomide \u2013 a revival story. N Engl J Med 341: 1606\u20131609","journal-title":"N Engl J Med"},{"key":"BF6601579_CR27","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1097\/00002030-199611000-00007","volume":"10","author":"G Reyes-Teran","year":"1996","unstructured":"Reyes-Teran G, Sierra-Madero JG, Martinez Del Cerro V, Arroyo-Figueroa H, Pasquetti A, Calva JJ, Ruiz-Palacios GM (1996) Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 10: 1501\u20131507","journal-title":"AIDS"},{"key":"BF6601579_CR28","unstructured":"Richardson PG, Schlossman RL, Hideshima T, Davies F, Le Blanc R, Catley L, Doss D, Kelly KA, McKennev M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo J, Chauhan D, Munshi N, Weller E, Thomas S, Zeldis J, Anderson KC (2001) A phase 1 study of oral CC-5013, an immunomodulatory thalidomide derivative, in patients with relapsed and refractory multiple myeloma. Presented at the American Society of Hematology 43rd Annual Meeting, Orlando, FL, 7\u201311 December"},{"key":"BF6601579_CR29","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","volume":"100","author":"PG Richardson","year":"2002","unstructured":"Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley L, Doss D, Kelly KA, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo J, Chauhan D, Balinski K, Zeldis J, Anderson KC (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100: 3063\u20133067","journal-title":"Blood"},{"key":"BF6601579_CR30","doi-asserted-by":"publisher","first-page":"364","DOI":"10.2165\/00002018-199512060-00002","volume":"12","author":"U Schuler","year":"1995","unstructured":"Schuler U, Ehninger G (1995) Thalidomide: rationale for renewed use in immunological disorders. Drug Saf 12: 364\u2013369","journal-title":"Drug Saf"},{"key":"BF6601579_CR31","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1097\/00002030-199506000-00025","volume":"9","author":"D Sharpstone","year":"1995","unstructured":"Sharpstone D, Rowbottom A, Nelson M, Gazzard B (1995) The treatment of microsporidial diarrhoea with thalidomide. AIDS 9: 658\u2013659","journal-title":"AIDS"},{"key":"BF6601579_CR32","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","volume":"89","author":"R Simon","year":"1997","unstructured":"Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89: 1138\u20131147","journal-title":"J Natl Cancer Inst"},{"key":"BF6601579_CR33","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddleman P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J, Barlogie B (1999) Antitumour activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565\u20131571","journal-title":"N Engl J Med"},{"key":"BF6601579_CR34","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1200\/JCO.2000.18.8.1614","volume":"18","author":"LE Spitler","year":"2000","unstructured":"Spitler LE, Grossbard ML, Ernstoff MS, Silver G, Jacobs M, Hayes FA, Soong SJ (2000) Adjuvant therapy of stage III and IV malignant melanoma using granulocyte\u2013macrophage colony-stimulating factor. J Clin Oncol 18: 1614\u20131621","journal-title":"J Clin Oncol"},{"key":"BF6601579_CR35","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1002\/1097-0142(20011101)92:9<2364::AID-CNCR1584>3.0.CO;2-P","volume":"92","author":"JE Tseng","year":"2001","unstructured":"Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El-Naggar AK, Roach JS, Ginsberg LE, Thall PF, Wang X, Teddy S, Lawhorn KN, Zentgraf RE, Steinhaus GD, Pluda JM, Abbruzzese JL, Hong WK, Herbst RS (2001) Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 92: 2364\u20132373","journal-title":"Cancer"},{"key":"BF6601579_CR36","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0016-5085(99)70277-5","volume":"117","author":"EA Vasiliauskas","year":"1999","unstructured":"Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, Zeldis JB, Targan IR (1999) An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn\u2019s disease. Gastroenterology 117: 1278\u20131287","journal-title":"Gastroenterology"},{"key":"BF6601579_CR37","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0140-6736(05)64206-7","volume":"350","author":"AR Wettstein","year":"1997","unstructured":"Wettstein AR, Meagher AP (1997) Thalidomide in Crohn\u2019s disease. Lancet 350: 1445\u20131446","journal-title":"Lancet"},{"key":"BF6601579_CR38","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1136\/bmj.298.6671.432","volume":"298","author":"M Youle","year":"1989","unstructured":"Youle M, Clarbour J, Farthing C, Connolly M, Hawkins D, Staughton R, Gazzard B (1989) Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. BMJ 298: 432","journal-title":"BMJ"},{"key":"BF6601579_CR39","unstructured":"Zangari M, Tricot G, Zeldis J, Eddlemon P, Saghafifar F, Barlogie B (2001) Results of phase 1 study of CC-5013 for the treatment of multiple myeloma patients who relapse after high dose chemotherapy. Presented at the American Society of Hematology 43rd Annual Meeting, Orlando, FL, 7\u201311 December"},{"key":"BF6601579_CR40","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/sj.bmt.1702444","volume":"25","author":"A Zomas","year":"2000","unstructured":"Zomas A, Anagnostopoulos N, Dimopoulos MA (2000) Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent. Bone Marrow Transplant 25: 1319\u20131320","journal-title":"Bone Marrow Transplant"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6601579.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6601579","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6601579.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:55:44Z","timestamp":1684414544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6601579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["BF6601579"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6601579","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}